Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody
These agreements will support Adlai Nortye’s ongoing Phase I trial evaluating AN4035, a pan-RAS(ON) inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid
Adlai Nortye partnered with two big pharma companies to test a new cancer drug. This shows other companies believe in their science enough to work together on it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.